A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141 ·Status: RECRUITING ·Phase: PHASE3

A Study of LY4060874 in Healthy Participants

NCT06709820 ·Status: COMPLETED ·Phase: PHASE1

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT06180278 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Ruxolitinib Treatment in Inclusion Body Myositis

NCT06536166 ·Status: RECRUITING ·Phase: PHASE2

Personalized Immunotherapeutic for Antibiotic-resistant Infection

NCT02508584 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

NCT07284797 ·Status: RECRUITING ·Phase: PHASE1

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

NCT06524687 ·Status: TERMINATED ·Phase: PHASE1

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

NCT02053896 ·Status: COMPLETED

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

NCT04705350 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Mirikizumab (LY3074828) in Healthy Participants

NCT02568423 ·Status: COMPLETED ·Phase: PHASE1

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

NCT04789850 ·Status: RECRUITING ·Phase: PHASE2

Myasthenia Gravis Inebilizumab Trial

NCT04524273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Natalizumab High Titer Immunogenicity and Safety

NCT00516893 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

NCT06649695 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

NCT02605525 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of LY3079514 in Healthy Participants

NCT02242903 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT01423110 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

NCT05295433 ·Status: RECRUITING ·Phase: PHASE1/PHASE2